Stay connected! Share and follow:

Leukaemia CARE Careline

We're here to talk | 24-hours a day

08088 010 444

FREE from landlines & most major mobile networks

16
Jan
New leukaemia treatment available for patients in Wales!

written by

Leukaemia Care, Charity

  • medication

It has been announced that the All Wales Medicines Strategy Group (AWMSG) has approved ponatinib as a treatment for patients with chronic myeloid leukaemia (CML) or acute lymphoblastic leukaemia (ALL) in Wales. Ponatinib is marketed by Ariad as Iclusig®.

Ponatinib has been accepted for the ‘treatment of adult patients with: chronic phase, accelerate phase, or blast phase chronic myeloid leukaemia (CML) who are resistant to dasatinib or nilotinib, who are intolerant to dasatinib or nilotinib and for whom subsequent treatment with imatinib is not clinically appropriate, or who have the T315I mutation; or Philadelphia chromosome-positive acute lymphoblastic leukaemia (Ph+ ALL) who are resistant to dasatinib, who are intolerant to dasatinib and for whom subsequent treatment with imatinib is not clinically appropriate, or who have the T315I mutation.

Ponatinib is expected to provide patients with another treatment option after they have exhausted previously available treatment options. As such the patient numbers expected to be treated with ponatinib are relatively small, but for those patients ponatinib may offer them a realistic treatment option where none was previously available.

Ponatinib is not currently available for NHS funding elsewhere within the UK. Within England the National Institute for Health and Care Excellence (NICE) has decided not to review ponatinib, noting that the population size is very small. The Scottish Medicines Consortium (SMC) is currently reviewing ponatinib for NHS patients in Scotland, with a decision expected later this year.

Monica Izmajlowicz, Leukaemia CARE’s Chief Executive, said: “We welcome the decision by the All Wales Medicines Strategy Group (AWMSG) which enables NHS patients in Wales to routinely access this treatment. We await the decision of the Scottish Medicines Consortium (SMC) to see whether patients in Scotland will also be able to access this treatment.”